Sulanda (surufatinib)

Acetonitrile was used to precipitate the plasma protein, and lenvatinib was employed as the internal standard (IS). This may be due to insufficient doses of myricetin, or failure of myricetin to act in a timely manner in vivo. The findings contributed to a better understanding of the metabolism and drug-drug interaction of sulfatinib, but the presence or absence of interactions needs to be confirmed by further studies.

P2, N=47, Recruiting, Sun Yat-sen University

P2, N=28, Active, not recruiting, Qilu Hospital of Shandong University | Recruiting --> Active, not recruiting | Trial primary completion date: May 2024 --> Dec 2024

P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=23, Not yet recruiting, Fujian Cancer Hospital

Common adverse reactions observed during surufatinib treatment include hypertension, proteinuria, bleeding events, and hepatic lab test abnormal and diarrhea. Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice (2024 edition) aims to provide standardized guidance for its rational use and enhance patient compliance to maximize therapeutic benefits.

P2, N=34, Suspended, Zhejiang Cancer Hospital | Recruiting --> Suspended

P1/2, N=40, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting

P2, N=37, Active, not recruiting, Bai-Rong Xia | N=20 --> 37

P2, N=74, Recruiting, Anhui Provincial Cancer Hospital | N=50 --> 74

P2, N=80, Not yet recruiting, RenJi Hospital

In this article, we report a patient with uSRCS who responded to treatment with anti-VEGF inhibitor surufatinib and anti-PD-1 inhibitor camrelizumab after progression on first-line chemotherapy, second-line anlotinib combined with immunotherapy, and third-line chemotherapy...The patient received 4 cycles of the Ifosfamide and epirubicin hydrochloride regimen, and her best objective response was stable disease...Thus, a regimen of gemcitabine plus docetaxel was adopted...As of April 2023, the patient had a progression-free survival time of 26 months. Surufatinib in combination with camrelizumab could be effective in the treatment of advanced uSRCSs.

P4, N=51, Recruiting, Jiangsu Province Hospital; Jiangsu Province Hospital | Not yet recruiting --> Recruiting

P2, N=23, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

Surufatinib has demonstrated a progression-free survival (PFS) of no less than 14 months, and the patient's survival has endured for a duration of 33 months. This indicates the potential efficacy of surufatinib as a viable therapeutic alternative for adult patients afflicted with PB.

P1/2, N=41, Recruiting, Shanghai Zhongshan Hospital | Trial primary completion date: Jun 2024 --> Nov 2024

P2, N=20, Not yet recruiting, Fudan University

P2, N=50, Recruiting, Anhui Provincial Cancer Hospital

P2, N=29, Not yet recruiting, National Cancer Center, China

P2/3, N=482, Recruiting, Hutchmed | Not yet recruiting --> Recruiting

P2, N=20, Active, not recruiting, Bai-Rong Xia | Recruiting --> Active, not recruiting

P1/2, N=83, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Feb 2024 --> Jul 2024

SUR combined with PDT can significantly enhance the inhibitory effect on CCA, and can be alleviated by two ferroptosis inhibitors (Ferrostatin-1, Deferoxamine). In conclusion, SUR combined with PDT exerted an anti-CCA effect by inducing ferroptosis. Combination therapy provides a new idea for the clinical treatment of CCA.

P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=160, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Jan 2024

P2/3, N=482, Not yet recruiting, Hutchmed

P2, N=40, Not yet recruiting, Wuhan Union Hospital, China

P=N/A, N=63, Not yet recruiting, Fudan University

P2, N=78, Active, not recruiting, Hutchmed | Trial primary completion date: Sep 2023 --> Sep 2024

P2, N=25, Recruiting, Qilu Hospital of Shandong University

P1/2, N=36, Active, not recruiting, Hutchison Medipharma Limited | Recruiting --> Active, not recruiting

P1/2, N=130, Completed, Hutchison Medipharma Limited | Active, not recruiting --> Completed

P1/2, N=13, Completed, Hutchmed | Active, not recruiting --> Completed

P2, N=34, Recruiting, Zhejiang Cancer Hospital

The insensitivity of sulfatinib to FGFR gatekeeper mutations highlights the indispensable interactions with the hydrophobic pocket for FGFR selectivity, whereas the rotatory flexibility may enable sulfatinib to overcome CSF-1R. This study not only sheds light on the structural basis governing sulfatinib's FGFR/CSF-1R inhibition, but also provides valuable insights into the rational design of dual- or multi-target FGFR inhibitors with selectivity for CSF-1R and sensitivity to gatekeeper mutations.

P2, N=20, Recruiting, Sun Yat-sen University

P2, N=41, Not yet recruiting, Wuhan Union Hospital, China

P2, N=18, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2023 --> Jun 2024

P3, N=194, Recruiting, Hutchison Medipharma Limited | Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Jul 2023 --> May 2025

P2, N=100, Not yet recruiting, Changhai Hospital

P=N/A, N=39, Not yet recruiting, Shanghai Changzheng Hospital

P2, N=41, Not yet recruiting, Wuhan Union Hospital, China